The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - GenesisCare; Telix Pharmaceuticals
89Zirconium-labelled girentuximab (89Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma.
 
Dickon Hayne
Consulting or Advisory Role - BMS; Urogen pharma
Research Funding - AstraZeneca (Inst); Telix Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - Abbott/AbbVie
 
Richard Gauci
No Relationships to Disclose
 
Mohammed Al-Zubaidi
No Relationships to Disclose
 
Pravin Viswambaram
No Relationships to Disclose
 
Steve P McCombie
No Relationships to Disclose
 
Elizabeth Chien Hern Liow
Travel, Accommodations, Expenses - Pfizer
 
Nat Lenzo
No Relationships to Disclose
 
Thomas Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Roche
 
Paola Antonini
Employment - Almirall
Honoraria - Great Health Science
Consulting or Advisory Role - Adrenomed (I)
Speakers' Bureau - Adrenomed (I)
Research Funding - Adrenomed (I)
Travel, Accommodations, Expenses - Almirall Hermal GmbH
 
Danielle Meyrick
No Relationships to Disclose
 
Colin Hayward
Employment - Telix Pharmaceuticals
Leadership - Telix Pharmaceuticals
 
Andrew David Redfern
Honoraria - AstraZeneca; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche